in ovarian cancer treatment
School of Medicine researchers have released laboratory-based data identifying significant new signaling pathways for ovarian cancer and have found that drugs can be used successfully to alter signals to induce cancer cell death.
The results were presented at the Society for Gynecologic Investigation's 50th Annual Meeting in Washington, D.C.
Researchers, led by Dr. Gil Mor and Dr. Thomas Rutherford, both associate professors in the Department of Obstetrics and Gynecology, used the experimental anti-cancer agent that caused chemo-resistant cancer cells to die. They also presented data indicating two signaling pathways that regulate cancer cells. They found that the drug, phenoxodiol, works by altering the signals made by these pathways.
"We've found that this drug is an efficient inducer of cell death in ovarian cancer cells and sensitizes the cancer cells to Fas-mediated apoptosis (cell death)," says Mor. "These findings demonstrate a novel non-toxic drug that controls FLIP/XIAP function and has the potential to eliminate tumor cells through Fas-mediated apoptosis."
A multi-center phase II trial is underway to investigate the drug phenoxodiol in women with chemo-resistant ovarian cancer. The trial is being conducted at the School of Medicine, the only participating U.S. site.
"In the laboratory, we have identified phenoxodiol to be an extremely effective agent in causing ovarian cancer cells to undergo cell death," says Rutherford. Clinically, we are investigating possible toxicity and response at different dose levels in women with chemo-resistant ovarian cancer. In some of these women, disease regression or stabilization has been realized."
Dr. Graham Kelly, director of phenoxodiol research at Marshall Edwards Inc., adds, "What's important here is not just the discovery that phenoxodiol causes chemo-resistant ovarian cancer cells to die, but also that they know how it makes that happen -- by altering the messages sent by two signaling pathways that otherwise fail to tell these cells to self-destruct."
-- By Karen Peart
T H I S
W E E K ' SS T O R I E S
Review committee suggests changes to enhance education in Yale College
'Feral' robot dogs trace pedigree to Yale engineer
Yale tutors show students how 'America Counts'
University holding more 'teach-ins' on war with Iraq
University issues health crisis alert for Yale travelers
Daily News alumni discuss how journalism has changed
Actor Christopher Reeve advocates for stem cell research
Dialogue about war in Iraq continues in campus events
Exhibit traces career of experimental British photographer
Yale to train future medical leaders in re-focused program
Study finds new drug holds promise in ovarian cancer treatment
Three students are awarded Goldwater Scholarships
Truman Scholarships given to two potential leaders
Adviser to Peru's former president to present Downey Lecture
OBITUARIESRenowned historian and national parks enthusiast Robin Winks
Frederic Holmes, a noted historian of science and medicine
Psychiatrist Dr. Ira Levine, former deputy director at YPI
Edward Hoffman, had served as director of operations at Yale
Yale Entrepreneurial Society will co-host 'Innovation Summit'
Book club event will feature a talk by Dr. Ben Carson
Yale hosts fifth Powwow
Discussion by scholars will examine the current state of affairs in China
Conference highlights graduate students' work . . .
Brudner Prize winner explores the history of sexuality in talk
Campus Notes
Bulletin Home|Visiting on Campus|Calendar of Events|In the News
Bulletin Board|Yale Scoreboard|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs Home|News Releases|
E-Mail Us|Yale Home Page